These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31802055)

  • 41. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography.
    Yokoyama S; Kajiya Y; Yoshinaga T; Tani A; Hirano H
    Psychogeriatrics; 2014 Jun; 14(2):110-7. PubMed ID: 24954834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility of in vivo
    Bucerius J; Barthel H; Tiepolt S; Werner P; Sluimer JC; Wildberger JE; Patt M; Hesse S; Gertz HJ; Biessen EAL; Mottaghy FM; Sabri O
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1119-1128. PubMed ID: 28321471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition.
    Baghel V; Tripathi M; Parida G; Gupta R; Yadav S; Kumar P; Dey AB; Damle NA; Kumar R; Bal C
    Clin Nucl Med; 2019 Nov; 44(11):e597-e601. PubMed ID: 31584490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
    Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
    Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
    J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of positron-emission tomography/single-photon emission computed tomography imaging probes for in vivo detection of beta-amyloid plaques in Alzheimer's brains.
    Ono M
    Chem Pharm Bull (Tokyo); 2009 Oct; 57(10):1029-39. PubMed ID: 19801854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiomics Analysis of Brain [
    Alongi P; Laudicella R; Panasiti F; Stefano A; Comelli A; Giaccone P; Arnone A; Minutoli F; Quartuccio N; Cupidi C; Arnone G; Piccoli T; Grimaldi LME; Baldari S; Russo G
    Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35453981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of cardiac amyloidosis with
    Kircher M; Ihne S; Brumberg J; Morbach C; Knop S; Kortüm KM; Störk S; Buck AK; Reiter T; Bauer WR; Lapa C
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1407-1416. PubMed ID: 30798427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new integrated dual time-point amyloid PET/MRI data analysis method.
    Cecchin D; Barthel H; Poggiali D; Cagnin A; Tiepolt S; Zucchetta P; Turco P; Gallo P; Frigo AC; Sabri O; Bui F
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2060-2072. PubMed ID: 28674847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
    Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
    J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
    Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Oh H; Madison C; Baker S; Rabinovici G; Jagust W
    Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Higashi T; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Okina T; Suzuki N; Hasegawa H; Nagahama Y; Ishizu K; Oishi N; Kimura H; Watanabe H; Ono M; Saji H; Yamauchi H
    Ann Nucl Med; 2018 Apr; 32(3):206-216. PubMed ID: 29388083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultra-Low-Dose
    Chen KT; Gong E; de Carvalho Macruz FB; Xu J; Boumis A; Khalighi M; Poston KL; Sha SJ; Greicius MD; Mormino E; Pauly JM; Srinivas S; Zaharchuk G
    Radiology; 2019 Mar; 290(3):649-656. PubMed ID: 30526350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification.
    Presotto L; Iaccarino L; Sala A; Vanoli EG; Muscio C; Nigri A; Bruzzone MG; Tagliavini F; Gianolli L; Perani D; Bettinardi V
    Neuroimage Clin; 2018; 20():153-160. PubMed ID: 30094164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
    Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
    Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of Amyloid PET Scans in the Evaluation of Patients Presenting with Diverse Cognitive Complaints.
    Shea YF; Barker W; Greig-Gusto MT; Loewenstein DA; DeKosky ST; Duara R
    J Alzheimers Dis; 2018; 66(4):1599-1608. PubMed ID: 30475766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.